Natera (NTRA) Gets a Buy Rating from Canaccord Genuity

By Carrie Williams

In a report released today, Mark Massaro from Canaccord Genuity maintained a Buy rating on Natera (NTRAResearch Report), with a price target of $44.00. The company’s shares closed last Monday at $39.22, close to its 52-week high of $39.53.

According to TipRanks.com, Massaro is a top 100 analyst with an average return of 22.9% and a 62.2% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Castle Biosciences Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Natera with a $42.00 average price target, representing a 9.9% upside. In a report issued on October 11, Piper Jaffray also maintained a Buy rating on the stock with a $45.00 price target.

See today’s analyst top recommended stocks >>

Based on Natera’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $32.42 million. In comparison, last year the company had a GAAP net loss of $29.62 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing.